|Bid||0.2636 x 800|
|Ask||0.2700 x 42300|
|Day's Range||0.2615 - 0.2950|
|52 Week Range||0.0700 - 2.8000|
|Beta (3Y Monthly)||4.31|
|PE Ratio (TTM)||N/A|
|Earnings Date||May 11, 2017 - May 12, 2017|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||2.00|
A Justice Department lawyer called for all bankruptcy professionals to improve transparency regarding potential conflicts of interest, likening recent disclosures filed by Centerview Partners to a “cat ...
# Synergy Pharmaceuticals Inc ### NASDAQ/NGS:SGYP View full report here! ## Summary * Bearish sentiment is moderate and declining ## Bearish sentiment Short interest | Positive Short interest is moderate for SGYP with between 5 and 10% of shares outstanding currently on loan. However, this was an improvement in sentiment as investors who seek to profit from falling equity prices reduced their short positions on December 19. ## Money flow ETF/Index ownership | Neutral ETF activity is neutral. The net inflows of $2.16 billion over the last one-month into ETFs that hold SGYP are not among the highest of the last year and have been slowing. ## Economic sentiment PMI by IHS Markit | Neutral According to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is strong relative to the trend shown over the past year, but is easing. ## Credit worthiness Credit default swap CDS data is not available for this security. Please send all inquiries related to the report to firstname.lastname@example.org. Charts and report PDFs will only be available for 30 days after publishing. This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.
Charlotte Russe Inc., a mall-based fast-fashion retailer, is reassessing its future, including a possible sale or bankruptcy, less than a year after reaching a deal with its lenders to slash debt.
Cos., formerly Valeant Pharmaceuticals International Inc., after agreeing to delay the process by two weeks. During a hearing Friday at the U.S. Bankruptcy Court in New York, Judge James Garrity Jr. said he was satisfied with the extension and was pleased to keep the process rolling forward. The judge had previously expressed concern about moving the sale along too quickly.
CORAL GABLES, FL / ACCESSWIRE / January 4, 2019 / The healthcare industry is predicated on the notion that as diseases become more advanced and difficult to treat, companies responsible for creating treatment options will rise to the occasion to assist patients suffering from said ailments. Premier Health Group (OTC:PHGRF) (CSE:PHGI), Synergy Pharmaceuticals Inc (SGYP), Novavax Inc (NVAX), and Epizyme Inc (EPZM) are 4 healthcare stocks representing companies invested in creating the best quality treatments for their patients. Premier Health Group (OTC:PHGRF) (CSE:PHGI) opened Friday with the Company's shares trading at $0.63 per share, well above the $0.53 close back in October, as well as steadily ahead of $0.59 per share price point from early last month.
CORAL GABLES, FL / ACCESSWIRE / January 2, 2019 / With the new year only a few days old, the healthcare sector is already showing signs that this year may prove exciting for the market. From data-based approaches and analysis consumer demands/needs, advancements in the sector may catalyze potential opportunities for those looking to healthcare. Premier Health Group (PHGRF) (PHGI), Regional Health Properties, Inc (NYSE: RHE), Genocea Biosciences Inc (NASDAQ: GNCA), and Synergy Pharmaceutical, Inc (NASDAQ: SGYP) are 4 healthcare stocks heating up on Wednesday.
From data-based care solutions to improved treatment options, Premier Health Group (PHGRF) (PHGI), Rite Aid Corporation (RAD), Adamis Pharmaceuticals Corp (ADMP), and Synergy Pharmaceuticals Inc (SGYP) are 4 pharma stocks heating up on Monday. Synergy Pharmaceuticals, Inc (SGYP) a biopharmaceutical company that is largely focused on developing originative gastrointestinal therapies, announced earlier this month that it had entered into an agreement with Bausch Health Companies Inc. through which Bausch Health would acquire substantially all of Synergy's assets, including all rights to TRULANCE®,dolcanatide and related intellectual property, for approximately $200 million in cash.
This is a summary of a request from Synergy Pharmaceuticals Inc. to hire Skadden Arps Slate Meagher & Flom LLP as counsel, filed Dec. 26 with the U.S. Bankruptcy Court in New York.
CORAL GABLES, FL / ACCESSWIRE / December 21, 2018 / The pharmaceutical industry is predicated on the notion that treatments for various ailments can always be improved upon, and patients suffering from these diseases both demand and need better treatment options. As pharmaceutical companies work to develop new methods for bettering the care provided to their patients, the industry, in its entirety may benefit from these efforts. Premier Health Group (OTC:PHGRF) (CSE:PHGI), Synergy Pharmaceuticals, Inc (SGYP), Pieris Pharmaceuticals, Inc (PIRS), and Obalon Therapeutics Inc (OBLN) are 4 pharma stocks representing companies invested in creating the best quality drug treatments for their patients.
Index (PMI) data, output in the Healthcare sector is rising. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.
CORAL GABLES, FL / ACCESSWIRE / December 19, 2018 / The pharmaceutical industry is booming with innovative approaches to developing quality treatment options for patients around the world. As demand for ...
NEW YORK, NY / ACCESSWIRE / December 18, 2018 / Shares of Achillion Pharmaceuticals were in the red on Monday as traders waited for interim clinical-trial data from the company. Synergy Pharmaceuticals saw its shares explode on news from Cipher Pharmaceuticals Inc. announcing that its New Drug Submission for plecanatide for irritable bowel syndrome with constipation ("IBS-C") has been accepted by Health Canada. Cipher acquired the Canadian rights to develop, market, distribute and sell plecanatide from Synergy earlier this year.
/ On Tuesday 12/18/2018, Premier Health Group, Inc. (OTC:PHGRF) (CSE:PHGI), Synergy Pharmaceuticals Inc. (SGYP), New Age Beverages Corporation (NBEV) and Uxin Limited (UXIN) are seeing pre-market "buzz". Premier Health Group, Inc. (OTC:PHGRF) (CSE:PHGI) has seen a strong month of bullish trading and shares of the company have climbed by as much as 31% over the last 30 days. The Company has been focusing on a growth strategy with key announcements which continue to build new interest.
On Monday 12/17/2018, Premier Health Group, Inc. (OTC:PHGRF) (CSE:PHGI), Diffusion Pharmaceuticals Inc. (DFFN), Evofem Biosciences, Inc. (EVFM) and Synergy Pharmaceuticals Inc. (SGYP) are presenting investors with upside opportunity ahead of Christmas and the 2019 New Year. Premier Health Group, Inc. (OTC:PHGRF) (CSE:PHGI) a company you may have not heard of yet, has seen a strong month of bullish trading and shares of the company have climbed by as much as 31% over the last 30 days. The Company has been focusing on a growth strategy with key announcements which continue to build new interest.
Neiman Marcus filed a counter lawsuit Friday against bondholder Marble Ridge Capital, accusing the investment firm of spreading false statements about the company being in default under its debt documents....
MISSISSAUGA, ON , Dec. 17, 2018 /CNW/ - Cipher Pharmaceuticals Inc. (CPH.TO) today announced that its New Drug Submission ("NDS") for plecanatide for irritable bowel syndrome with constipation ("IBS-C") has been accepted by Health Canada. Cipher acquired the Canadian rights to develop, market, distribute and sell plecanatide (branded as TRULANCE® in the U.S.) from Synergy Pharmaceuticals Inc. (SGYP) ("Synergy") in February 2018 . It is estimated that one in four Canadians has symptoms of constipation and an estimated 38% of Canadians report constipation within the previous 12 months1.
During a hearing Thursday at the U.S. Bankruptcy Court in New York, Judge James Garrity Jr. expressed concern about moving too quickly but authorized the company to continue to pay employees, access bank accounts and maintain other routine operations. Inc., formerly known as Valeant Pharmaceuticals International Inc., for around $200 million in cash.
NEW YORK, NY / ACCESSWIRE / December 13, 2018 / Shares of both Neurocrine Biosciences and Synergy Pharmaceuticals were in the red on Wednesday after announcing discouraging developments. Synergy is selling its business assets while Neurocrine Biosciences failed to meet a primary goal in a mid-stage trial. Neurocrine Biosciences, Inc. shares were down almost 14% on about 13 million shares traded yesterday.
Synergy Pharmaceuticals Inc. filed for bankruptcy Wednesday with a plan to sell its assets to Bausch Health Companies Inc. for around $200 million in cash. The deal includes all rights to Synergy’s flagship product Trulance, a tablet approved for adults with chronic idiopathic constipation and irritable bowel syndrome with constipation, as well as another development-stage compound and related intellectual property. “We have worked diligently to serve our patients, health care professionals and other stakeholders by bringing Trulance to market and developing other [gastrointestinal] therapies to address previously unmet needs,” said Synergy Chief Executive Troy Hamilton.
Synergy Pharmaceuticals (NASDAQ:SGYP) has filed for Chapter 11 bankruptcy in a voluntary petition with another pharmaceutical company absorbing most of the company’s assets once the move goes through. The bankruptcy filing will be followed by Bausch Health (NYSE:BHC) taking over as a “stalking horse” bidder for the company in an auction and sale process that has been approved by a court. The acquisition of Synergy’s assets will be part of a deal valued at roughly $200 million that is slated to be complete at the end of the first quarter of 2019.
The problem doesn’t appear to have been the stigma around talking about bowel movements — an issue Synergy hoped to address with those (animated!) emojis — but rather a highly competitive market.(2)Trulance has made little headway against better established drugs like Allergan PLC’s Linzess and Takeda Pharmaceutical Co.’s Amitiza.
, formerly known as Valeant Pharmaceuticals, is back in the acquisitions game after a long hiatus. The deal gives Bausch access to Synergy’s lead drug Trulance, which treats irritable bowel syndrome. The deal is Bausch’s first major acquisition since 2015.
Synergy Pharmaceuticals Inc. shares slid 55% in premarket trade Wednesday, after the company filed a voluntary petition for Chapter 11, allowing Bausch Health Cos. Inc. to serve as "stalking horse" bidder for the company in a court-approved auction and sale processes. Bausch, the former Valeant, will acquire Synergy's assets in a deal valued at about $200 million that is expected to close in the first quarter of 2019. Synergy specializes in gastrointestinal therapies, including its flagship Trulance product, a once-a-day table approved for adults with chronic constapion and irritable bowel syndrome with constipation. That product will complement Bausch's Salix business, Chief Executive Joseph Papa said in a statement. Bausch shares were up slightly premarket, and have gained 11% in 2018, while the S&P 500 has fallen 1.4%.
LAVAL, Quebec, Dec. 12, 2018 /PRNewswire/ -- Bausch Health Companies Inc. (NYSE/TSX: BHC) ("Bausch Health" or the "Company") announced today that it has entered into a definitive agreement to acquire certain assets of Synergy Pharmaceuticals Inc. (SGYP) ("Synergy") in a transaction valued at approximately $200 million plus certain assumed liabilities. Synergy filed a voluntary petition for reorganization under Chapter 11 of the U.S. Code (the "Bankruptcy Code") with the U.S. Bankruptcy Court for the Southern District of New York (the "Bankruptcy Court") earlier today. Under the terms of the agreement, and subject to Bankruptcy Court approval, Bausch Health will serve as the "stalking horse" bidder in a court-supervised auction and sale process, which Synergy will conduct pursuant to Section 363 of the Bankruptcy Code.